Payment overview · 2025
General Payments
$169.20
9 reported records · 6 companies
Healthcare provider profile · identity verified
Seth Aaron Stambaugh, DO
Allopathic & Osteopathic Physicians|Family Medicine · DURANT, OK · NPI 1730706219
Verified facts
What the public records show
CMS Open Payments records show Seth Aaron Stambaugh, DO received $169.20 in general payments during 2025 across 9 reported records.
ABBVIE INC. accounted for 33.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 8 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported HUMIRA as an associated drug or biological on 1828 records involving 689 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Humira by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Vraylar by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABILIFY MAINTENA as an associated drug or biological on 2902 records involving 986 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Abilify Maintena by this doctor in 2024.
Lundbeck LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 71829 records involving 25812 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 54 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $55.78 | 33.0% | 3 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $40.08 | 23.7% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $22.96 | 13.6% | 1 | 2025 |
| Alkermes, Inc. | Unresolved — no canonical attribution shown | $21.63 | 12.8% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$14.40 | 8.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $14.35 | 8.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $169.20 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $40.08 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.27 | 2 | 2025 |
Source payment records
|
|||||
| ABILIFY ASIMTUFII Normalized: abilify asimtufii |
Drug | Lundbeck LLC | $22.96 | 1 | 2025 |
Source payment records
|
|||||
| LYBALVI Normalized: lybalvi |
Drug | Alkermes, Inc. | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| MAVYRET Normalized: mavyret |
Drug | ABBVIE INC. | $18.51 | 1 | 2025 |
Source payment records
|
|||||
| INCEPTIV Normalized: inceptiv |
Device | Medtronic, Inc. | $14.40 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.35 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 54 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 22 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | HUMIRA open payments reported associated product |
CMS Open Payments — General Payments 1828 supporting records · 689 recipient NPIs · example record 1201353784 |
Humira · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | ABILIFY MAINTENA open payments reported associated product |
CMS Open Payments — General Payments 2902 supporting records · 986 recipient NPIs · example record 1251759994 |
Abilify Maintena · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lundbeck LLC Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 71829 supporting records · 25812 recipient NPIs · example record 1251759986 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
54 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 217 | 74 |
| Gabapentin | Gabapentin | 204 | 56 |
| Escitalopram Oxalate | Escitalopram Oxalate | 162 | 42 |
| Furosemide | Furosemide | 156 | 41 |
| Lisinopril | Lisinopril | 144 | 47 |
| Levothyroxine Sodium | Levothyroxine Sodium | 142 | 41 |
| Atorvastatin Calcium | Atorvastatin Calcium | 141 | 50 |
| Meloxicam | Meloxicam | 127 | 35 |
| Losartan Potassium | Losartan Potassium | 119 | 42 |
| Amlodipine Besylate | Amlodipine Besylate | 112 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 112 | 26 |
| Alprazolam | Alprazolam | 102 | 32 |
| Trazodone Hcl | Trazodone Hcl | 96 | 30 |
| Omeprazole | Omeprazole | 93 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 93 | 21 |
| Aripiprazole | Aripiprazole | 89 | 26 |
| Clonazepam | Clonazepam | 84 | 29 |
| Potassium Chloride | Potassium Chloride | 84 | 22 |
| Quetiapine Fumarate | Quetiapine Fumarate | 83 | 27 |
| Eszopiclone | Eszopiclone | 81 | 17 |
| Pantoprazole Sodium | Pantoprazole Sodium | 80 | 28 |
| Metformin Hcl | Metformin Hcl | 78 | 24 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 25 |
| Montelukast Sodium | Montelukast Sodium | 75 | 26 |
| Prednisone | Prednisone | 74 | 60 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 67 | 27 |
| Mounjaro | Tirzepatide | 67 | suppressed |
| Pregabalin | Pregabalin | 62 | 18 |
| Eliquis | Apixaban | 61 | 15 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 60 | 15 |
| Ropinirole Hcl | Ropinirole Hcl | 57 | 18 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 57 | 13 |
| Ozempic | Semaglutide | 54 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 53 | 13 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 53 | 12 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 53 | 15 |
| Tramadol Hcl | Tramadol Hcl | 53 | 28 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 51 | 15 |
| Carvedilol | Carvedilol | 48 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 48 | suppressed |
| Temazepam | Temazepam | 48 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 44 | 28 |
| Doxycycline Hyclate | Doxycycline Hyclate | 43 | 36 |
| Jardiance | Empagliflozin | 40 | suppressed |
| Spironolactone | Spironolactone | 40 | 12 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 40 | 30 |
| Donepezil Hcl | Donepezil Hcl | 39 | 15 |
| Metformin Hcl Er | Metformin Hcl | 37 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 37 | 13 |
| Celecoxib | Celecoxib | 36 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 36 | 12 |
| Buspirone Hcl | Buspirone Hcl | 35 | suppressed |
| Bupropion Xl | Bupropion Hcl | 34 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 34 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 34 | 12 |
| Mupirocin | Mupirocin | 34 | 21 |
| Ondansetron Odt | Ondansetron | 33 | 19 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 32 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 30 | 15 |
| Mirtazapine | Mirtazapine | 29 | suppressed |
| Abilify Maintena | Aripiprazole | 28 | suppressed |
| Tamsulosin Hcl | Tamsulosin Hcl | 28 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 27 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 27 | suppressed |
| Sucralfate | Sucralfate | 26 | suppressed |
| Topiramate | Topiramate | 26 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 25 | 22 |
| Famotidine | Famotidine | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | 12 |
| Prazosin Hcl | Prazosin Hcl | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 23 | suppressed |
| Olanzapine | Olanzapine | 23 | suppressed |
| Vraylar | Cariprazine Hcl | 22 | suppressed |
| Lamotrigine | Lamotrigine | 21 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 21 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 21 | suppressed |
| Simvastatin | Simvastatin | 20 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | suppressed |
| Finasteride | Finasteride | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Memantine Hcl | Memantine Hcl | 18 | suppressed |
| Risperidone | Risperidone | 18 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 18 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 17 | suppressed |
| Trulicity | Dulaglutide | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 15 | 13 |
| Glipizide Er | Glipizide | 15 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 15 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 15 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 15 | suppressed |
| Butorphanol Tartrate | Butorphanol Tartrate | 14 | suppressed |
| Etodolac | Etodolac | 14 | suppressed |
| Methocarbamol | Methocarbamol | 14 | suppressed |
| Azithromycin | Azithromycin | 13 | 13 |
| Estradiol | Estradiol | 13 | suppressed |
| Fluconazole | Fluconazole | 13 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | 12 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 12 | suppressed |
| Humira | Adalimumab | 12 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Carbamazepine | Carbamazepine | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $169.20 · 9 records | ABBVIE INC. | ABILIFY ASIMTUFII, INCEPTIV, LYBALVI, MAVYRET, OTEZLA, Ozempic, REPATHA, VRAYLAR | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error